News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
466,218 Results
Type
Article (26986)
Company Profile (126)
Press Release (439106)
Multimedia
Podcasts (111)
Webinars (14)
Section
Business (140883)
Career Advice (1497)
Deals (22124)
Drug Delivery (69)
Drug Development (56921)
Employer Resources (100)
FDA (9795)
Job Trends (9680)
News (232720)
Policy (20105)
Tag
Academia (1618)
Academic (1)
Accelerated approval (16)
Adcomms (14)
Allergies (96)
Alliances (37811)
ALS (125)
Alzheimer's disease (1124)
Antibody-drug conjugate (ADC) (208)
Approvals (10081)
Artificial intelligence (369)
Autoimmune disease (104)
Automation (27)
Bankruptcy (185)
Best Places to Work (7963)
BIOSECURE Act (7)
Biosimilars (128)
Biotechnology (90)
Bladder cancer (116)
Brain cancer (38)
Breast cancer (447)
Cancer (3485)
Cardiovascular disease (283)
Career advice (1293)
Career pathing (28)
CAR-T (192)
CDC (24)
Cell therapy (528)
Cervical cancer (24)
Clinical research (49310)
Collaboration (1316)
Company closure (1)
Compensation (741)
Complete response letters (27)
COVID-19 (1711)
CRISPR (66)
C-suite (554)
Cystic fibrosis (104)
Data (4829)
Decentralized trials (2)
Denatured (38)
Depression (93)
Diabetes (361)
Diagnostics (3874)
Digital health (25)
Diversity (7)
Diversity, equity & inclusion (30)
Drug discovery (188)
Drug pricing (100)
Drug shortages (22)
Duchenne muscular dystrophy (154)
Earnings (64524)
Editorial (38)
Employer branding (12)
Employer resources (88)
Events (76790)
Executive appointments (690)
FDA (11988)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (5)
Frontotemporal dementia (17)
Funding (950)
Gene editing (131)
Generative AI (38)
Gene therapy (424)
GLP-1 (661)
Government (2608)
Grass and pollen (6)
Guidances (332)
Healthcare (11136)
HIV (43)
Huntington's disease (29)
IgA nephropathy (62)
Immunology and inflammation (151)
Immuno-oncology (35)
Indications (70)
Infectious disease (1865)
Inflammatory bowel disease (136)
Inflation Reduction Act (12)
Influenza (68)
Intellectual property (174)
Interviews (271)
IPO (11238)
IRA (31)
Job creations (2074)
Job search strategy (1065)
Kidney cancer (12)
Labor market (46)
Layoffs (270)
Leadership (27)
Legal (4801)
Liver cancer (51)
Longevity (8)
Lung cancer (493)
Lymphoma (286)
Machine learning (27)
Management (32)
Manufacturing (543)
MASH (135)
Medical device (7000)
Medtech (7024)
Mergers & acquisitions (11701)
Metabolic disorders (875)
Multiple sclerosis (116)
NASH (12)
Neurodegenerative disease (194)
Neuropsychiatric disorders (52)
Neuroscience (1951)
NextGen: Class of 2026 (3839)
Non-profit (2804)
Now hiring (13)
Obesity (373)
Opinion (203)
Ovarian cancer (102)
Pain (137)
Pancreatic cancer (147)
Parkinson's disease (185)
Partnered (21)
Patents (329)
Patient recruitment (301)
Peanut (35)
People (37582)
Pharmaceutical (37)
Pharmacy benefit managers (14)
Phase I (15031)
Phase II (21541)
Phase III (16632)
Pipeline (3763)
Policy (160)
Postmarket research (1831)
Preclinical (6365)
Press Release (43)
Prostate cancer (201)
Psychedelics (25)
Radiopharmaceuticals (209)
Rare diseases (556)
Real estate (3314)
Recruiting (41)
Regulatory (15569)
Reports (28)
Research institute (1515)
Resumes & cover letters (222)
Rett syndrome (19)
RNA editing (10)
RSV (45)
Schizophrenia (118)
Series A (156)
Series B (112)
Service/supplier (4)
Sickle cell disease (68)
Special edition (13)
Spinal muscular atrophy (98)
Sponsored (28)
Startups (2053)
State (1)
Stomach cancer (10)
Supply chain (61)
Tariffs (41)
The Weekly (72)
Vaccines (627)
Venture capital (47)
Weight loss (226)
Women's health (45)
Worklife (13)
Date
Today (16)
Last 7 days (443)
Last 30 days (1466)
Last 365 days (22806)
2026 (1119)
2025 (22833)
2024 (25258)
2023 (28320)
2022 (35776)
2021 (38198)
2020 (36017)
2019 (29894)
2018 (22056)
2017 (21928)
2016 (21014)
2015 (24497)
2014 (20368)
2013 (17322)
2012 (17286)
2011 (16856)
2010 (15909)
Location
Africa (605)
Alabama (62)
Alaska (4)
Arizona (140)
Arkansas (9)
Asia (28370)
Australia (4436)
California (8136)
Canada (2191)
China (869)
Colorado (348)
Connecticut (356)
Delaware (262)
Europe (64116)
Florida (1253)
Georgia (261)
Idaho (27)
Illinois (552)
India (41)
Indiana (406)
Iowa (16)
Japan (310)
Kansas (93)
Kentucky (25)
Louisiana (9)
Maine (33)
Maryland (993)
Massachusetts (6016)
Michigan (216)
Minnesota (352)
Mississippi (2)
Missouri (59)
Montana (11)
Nebraska (12)
Nevada (78)
New Hampshire (34)
New Jersey (2444)
New Mexico (17)
New York (2186)
North Carolina (1044)
North Dakota (5)
Northern California (4022)
Ohio (227)
Oklahoma (15)
Oregon (26)
Pennsylvania (1643)
Puerto Rico (9)
Rhode Island (27)
South America (834)
South Carolina (31)
Southern California (3217)
Tennessee (119)
Texas (1193)
United States (28906)
Utah (233)
Vermont (1)
Virginia (182)
Washington D.C. (57)
Washington State (619)
West Virginia (2)
Wisconsin (62)
Wyoming (2)
466,218 Results for "zhenxing biopharmaceutical and chemical".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
1910 Publishes CANDID-CNS™, an AI Model That Unlocks Beyond Rule of 5 Chemical Space and Stereochemistry to Predict Blood–Brain Barrier Penetration
● CANDID-CNS™ is the new state-of-the-art AI model for BBB penetration: it achieves 87% AUPRC on bRo5 small molecules compared to 56% by Pfizer’s CNS MPO. ● CANDID-CNS™ distinguishes CNS penetrant stereoisomers at 68% compared to 50% by Pfizer’s CNS MPO. ● Published in the Journal of Chemical Information and Modeling, CANDID-CNS™ presents a breakthrough in AI Drug Discovery by unlocking the potential of bRo5 and stereochemistry to significantly expand the chemical space of small molecules that can be developed into CNS therapeutics.
December 4, 2025
·
1 min read
Press Releases
Thermo Fisher Scientific Expands Gibco™ Bacto™ Portfolio with Next-Generation, Chemically Defined Media to Boost E. coli Biomanufacturing Productivity
December 16, 2025
·
4 min read
Press Releases
Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit
January 8, 2026
·
2 min read
Press Releases
Rakuten Medical and LOTTE Biologics Sign Manufacturing Agreement to Support Biopharmaceuticals in Global Oncology Program
January 14, 2026
·
5 min read
Press Releases
Day One Biopharmaceuticals to Acquire Mersana Therapeutics
November 13, 2025
·
10 min read
Press Releases
Angitia Biopharmaceuticals Completes Enrollment of Phase 2 ARTEMIS Trial Evaluating AGA2118 for the Treatment of Osteoporosis
January 5, 2026
·
5 min read
Press Releases
Angitia Biopharmaceuticals Announces Dosing of First Participant in Phase 2 IDUN Trial of AGA2115 for the Treatment of Osteogenesis Imperfecta
January 12, 2026
·
5 min read
Press Releases
Datavant and UBC Partner to Transform Observational Research and Patient Access for Biopharmaceutical Sponsors
November 21, 2025
·
4 min read
Press Releases
Kodiak Sciences to Present at American Chemical Society Fall 2025
August 20, 2025
·
5 min read
Rethinking Chemical Procurement in Biopharmaceuticals
Disruptions in the chemical supply chain can have severe consequences for R&D and drug manufacturing. Here’s how to avoid them.
September 26, 2023
·
5 min read
·
Dave Haase
1 of 46,622
Next
